TC BioPharm (NASDAQ: TCBP), a clinical stage biotechnology company developing allogeneic gamma-delta T cell therapies for cancer and other indications, is announcing the execution of a non-binding letter of intent (“LOI”). According to the announcement, the LOI is part of the company’s M&A strategy intended to expand its therapeutic platform and leverage natural killer (“NK”) cells to treat solid tumors and other indications. The target asset acquisition covers the proprietary manufacturing process of two allogeneic CAR-NK therapeutics, both of which the company believes are valuable as monotherapies and in conjunction with TCB-008 in the future. The terms of the LOI grant TC BioPharma exclusivity while the parties work on drafting a definitive agreement.
“We believe this proposed asset acquisition brings not just a new and expanded opportunity in cancer, but synergies in combination efforts with TCB-008 in numerous indications. This proposed asset acquisition would leverage our strengths in optimizing manufacturing processes and developing new cell therapies rapidly to the clinical stage, as well as our core asset on asset base expansion and combination efforts with TCB-008,” said Mr. Bryan Kobel, CEO of TC BioPharm.
To view the full press release, visit https://ibn.fm/AX1AZ
About TC BioPharm (Holdings) PLC
TC BioPharm is a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of gamma-delta T cell therapies for the treatment of cancer with human efficacy data in acute myeloid leukemia. Gamma-delta T cells are naturally occurring immune cells that embody properties of both the innate and adaptive immune systems and can intrinsically differentiate between healthy and diseased tissue. TC BioPharm is the leader in developing gamma-delta T cell therapies, and the first company to conduct phase II/pivotal clinical studies in oncology. The company is conducting two investigator-initiated clinical trials for its unmodified gamma-delta T cell product line – Phase 2b/3 pivotal trial for OmnImmune(R) in treatment of acute myeloid leukemia using the company’s proprietary allogeneic CryoTC technology to provide frozen product to clinics worldwide. For more information about the company, visit www.tcbioparm.com.
About InvestorWire
InvestorWire (“IW”) is a specialized communications platform with a focus on advanced wire-grade press release syndication for private and public companies and the investment community. It is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, IW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, IW brings its clients unparalleled recognition and brand awareness. IW is where breaking news, insightful content and actionable information converge.
For more information, please visit https://www.InvestorWire.com
Please see full terms of use and disclaimers on the InvestorWire website applicable to all content provided by IW, wherever published or re-published: https://www.InvestorWire.com/Disclaimer
InvestorWire
Los Angeles, CA
www.InvestorWire.com
310.299.1717 Office
[email protected]
InvestorWire is powered by IBN